TruBridge Inc Dossier
|
SectorHealth Care IndustryHealth Care Technology Beta (adjusted)1.19 Intrinsic Value $7.14median of 3 methodsbased on filings through 31 Mar 2026 Market Price $26.24Price as of 8 Jul 2026 Significantly overvaluedIntrinsic value is 73% below the market price −50% · IV below pricenear fair value ±15%IV above price · +50% marker beyond scale (-73%) Data confidence Sign in to view data confidence Market Cap $393.6M Enterprise Value $522M Shares Outstanding 14.7M diluted Moat Rating None Last ex-dividend14 Aug 2020 All prices and values are periodic snapshots, not live quotes. Source dates are shown for reference. ThesisStreet consensus, scenarios, merits, risks, and invalidation triggers Thesis Summary TruBridge, Inc. is currently in a definitive agreement to be acquired by Inventurus Knowledge Solutions, Inc. (IKS Health) for $26.25 per share in cash, representing an enterprise value of approximately $557 million. The transaction is expected to close in the third calendar quarter of 2026, subject to customary closing conditions, including regulatory clearances and shareholder approvals. Given that the stock is trading very close to the acquisition price of $26.25, there is limited remaining upside, and the investment thesis is primarily driven by merger arbitrage dynamics and the high probability of deal completion. This section is the 12-month view: analyst targets and the probability-weighted scenarios built from them. The intrinsic value at the top of this page answers a different question: what the business is worth today. Street view · analyst 12-month targets Low · most bearish analyst$23.00 Mean target$25.44 High · most bullish analyst$26.25 Our research · scenarios, merits, risks, and invalidation triggersResearch as of 20 Jun 2026 Scenarios · 12-month scenario targets Bear CaseDownside scenario $17.00 The merger fails to close due to regulatory hurdles, financing issues, or failure to obtain the necessary shareholder approvals. In this downside scenario, the stock would likely re-rate sharply lower back to its pre-announcement trading range of $15.00 to $18.00, reflecting standalone operational challenges and material weaknesses in internal controls. Base CaseCentral scenario $26.25 The transaction proceeds as planned, receiving approval from TruBridge stockholders at the special meeting on July 7, 2026, as well as the necessary regulatory clearances and Indian shareholder approvals for IKS TopCo. The deal closes in Q3 2026, and shareholders receive the agreed-upon cash consideration of $26.25 per share. Bull CaseUpside scenario $26.25 The merger closes smoothly and ahead of schedule in Q3 2026, allowing arbitrageurs to capture the remaining spread with minimal holding time. Alternatively, a superior unsolicited bid emerges from another strategic or private equity buyer during the pre-closing period, though this is highly unlikely given the comprehensive strategic review already conducted. Scenarios are anchored to street consensus at the research date, with our probabilities and rationale. Key Investment Merits
Key Investment Risks
Thesis Invalidation Triggers
All scenarios are estimates and subject to change. Past performance is not indicative of future results. Quality Pillars MembersThis section is available to registered members. Create a free account or sign in to unlock the full breakdown. Explore this dossierValuationIntrinsic value, the six-method breakdown, peer medians, and your assumptions sandbox.Financial SnapshotRevenue, profitability, returns, balance sheet, dividends, and the filing-level detail.Qualitative AnalysisBusiness overview, strategic initiatives, and mergers, acquisitions & partnerships.Outlook & Key DatesForward estimates, reporting calendar, and the monitoring framework. |